Protein kinase B (PKB/Akt) has been shown to play a role in protection from apoptosis, cell proliferation and cell growth. It is also involved in mediating the effects of insulin, such as lipogenesis, glucose uptake and conversion of glucose into fatty acids and cholesterol. Sterolregulatory element binding proteins (SREBPs) are the major transcription factors that regulate genes involved in fatty acid and cholesterol synthesis. It has been postulated that constitutive activation of the phosphatidylinositol 3 kinase/Akt pathway may be involved in fatty acid and cholesterol accumulation that has been described in several tumour types. In this study, we have analysed changes in gene expression in response to Akt activation using DNA microarrays. We identified several enzymes involved in fatty acid and cholesterol synthesis as targets for Akt-regulated transcription. Expression of these enzymes has previously been shown to be regulated by the SREBP family of transcription factors. Activation of Akt induces synthesis of full-length SREBP-1 and SREBP-2 proteins as well as expression of fatty acid synthase (FAS), the key regulatory enzyme in lipid biosynthesis. We also show that Akt leads to the accumulation of nuclear SREBP-1 but not SREBP-2, and that activation of SREBP is required for Akt-induced activation of the FAS promoter. Finally, activation of Akt induces an increase in the concentration of cellular fatty acids as well as phosphoglycerides, the components of cellular membranes. Our data indicate that activation of SREBP by Akt leads to the induction of key enzymes of the cholesterol and fatty acid biosynthesis pathways, and thus membrane lipid biosynthesis.
Introduction
The serine threonine kinase Akt (PKB/Akt) is a downstream effector of phosphatidylinositol 3 kinase (PI3-kinase) and has been found to be involved in promoting cell survival in the presence of different apoptotic stimuli (Vivanco and Sawyers, 2002; Brazil et al., 2004) . Although some of the substrates of Akt, such as Bad, are directly involved in the regulation of apoptosis, it has been recognized that regulation of transcription by Akt may contribute to its prosurvival function (Brunet et al., 2001) . Akt is also an important mediator of the metabolic effects of insulin in several important physiological target tissues. Akt stimulates glucose uptake, glycogen synthesis, protein synthesis and lipogenesis in muscle and adipose tissue, resulting in the reduction of circulating glucose levels (Whiteman et al., 2002) . Akt is also involved in mediating insulininduced inhibition of glucogenolysis in the liver, possibly by regulating expression of the genes for glucose-6-phosphatase (Nakae et al., 2001 ) and phosphoenolpyruvate carboxykinase (Barthel et al., 2001) . Akt has been implicated in promoting cell cycle progression by regulating cyclin D1 stability (Diehl et al., 1998) and modulating expression and subcellular localization of the cdk inhibitors p27KIP1 Shin et al., 2002) and p21WAF1 (Zhou et al., 2001) . In addition, the PI3-kinase/Akt pathway has been implicated in the regulation of cell size and it was recently shown that Akt phosphorylates and inhibits TSC2 leading to the activation of p70S6-kinase, which results in increased protein synthesis (Potter et al., 2002) .
Akt has been shown to regulate the activity of a number of transcription factors, most notably the FoxO family of transcriptional regulators (Burgering and , which are directly phosphorylated by Akt resulting in inactivation of the transcription factors by cytoplasmic retention (del Peso et al., 1999; Kops et al., 1999; Takaishi et al., 1999) . Other transcription factors that are regulated by Akt are CREB and NF-kB. Akt phosphorylation of CREB increases binding to CBP and enhances CREB transcriptional activity (Pugazhenthi et al., 1999) . The regulation of NF-kB by Akt is somewhat less clear but may involve phosphorylation of IKK, resulting in the dissociation of the inhibitory factor IkB and nuclear translocation of transcriptionally active NF-kB (Romashkova and Makarov, 1999) . NF-kB induces expression of several prosurvival genes, such as Bfl-1 and IAP1/2, which may contribute to the antiapoptotic effect of Akt activation (Wang et al., 1998; Zong et al., 1999) .
Sterol-regulatory element binding proteins (SREBPs) consist of three closely related transcription factors, SREBP-1a, SREBP-1c and SREBP-2 (Eberle et al., 2004) . They have been identified as mediators of the effect of sterols on expression of enzymes involved in lipid and cholesterol homoeostasis (Yokoyama et al., 1993) . SREBP-1c (also termed ADD1) has been described independently as a factor involved in adipocyte differentiation (Tontonoz et al., 1993) . SREBPs belong to the family of basic helix-loop-helix-leucine zipper (bHLH-Zip) transcription factors and consist of an N-terminal transactivation domain, the bHLH-Zip DNA-binding domain and two hydrophobic transmembrane domains (Yokoyama et al., 1993) . They are synthesized as inactive precursors bound to the endoplasmic reticulum (ER) Brown and Goldstein, 1999) . In order to be transcriptionally active, the N-terminal part of the SREBP protein has to be cleaved by a mechanism termed regulated intramembrane processing Rawson, 2003) . When intracellular sterol concentrations are low, SREBPs are bound to the SREBP cleavage-activating protein (SCAP) and escorted to the Golgi apparatus where two proteolytic steps are required to release the transcriptionally active N-terminal part of the protein, which then translocates to the nucleus Yang et al., 2002) . When sterol concentrations are high, another protein, termed INSIG, binds to SCAP and prevents translocation of the SREBP/SCAP complex resulting in the inhibition of SREBP-dependent transcription (Yang et al., 2002) .
SREBPs bind to DNA sequences that contain a direct repeat of 5 0 -PyCAPy-3 0 , designated the sterolregulatory element (SRE). SREs are found in the promoter regions of a number of genes involved in cholesterol and fatty acid biosynthesis. Studies in knockout and transgenic mice have shown that SREBP-1c preferentially regulates genes involved in fatty acid biosynthesis, while SREBP-2 mainly regulates genes of the cholesterol pathway (Horton et al., 2003) . SREBP-1a also shows a preference for genes involved in fatty acid biosynthesis albeit less pronounced than that of SREBP-1c (Amemiya-Kudo et al., 2002) . More recently, selective binding of different SREBP isoforms to target promoters was analysed using chromatin IP (Bennett et al., 2004) . This study showed that SREBP-1a but not SREBP-1c can bind to SREs in the HMG-CoAreductase and fatty acid synthase (FAS) promoters, resulting in the recruitment of histone acetylase. SREBP-1a and SREBP-1c also differ in their binding to transcriptional coactivators, such as CBP and mammalian mediator complex, which may explain the low transcriptional activity of SREBP-1c .
A number of studies have addressed the regulation of SREBP gene expression in vivo and in vitro. SREBP-1a is expressed at low constitutive levels in vivo, but appears to be the predominant form in cultured cells (Shimomura et al., 1997) . The expression of SREBP-1c and SREBP-2 seems to be subject to distinct regulation in vivo. Both genes contain SREs in their promoter region (Sato et al., 1996; Amemiya-Kudo et al., 2000) and regulation through a feed-forward loop has been described in transgenic animals overexpressing the different SREBP proteins (Horton et al., 2003) . Transcription from the SREBP-1c promoter is modulated by insulin (Shimomura et al., 1999; Fleischmann and Iynedjian, 2000) . In addition, sterols have been shown to activate SREBP-1c expression by inducing binding of liver X-activated receptors (LXR) to binding sites on the promoter (Repa et al., 2000; Deng et al., 2002; Bobard et al., 2005) .
Although aberrant cholesterol and fatty acid biosynthesis have been mainly linked to metabolic abnormalities like diabetes and obesity, it has been postulated that deregulation of SREBP controlled gene expression could contribute to cell transformation and tumour development (Swinnen et al., 2004) . The accumulation of fatty acids and cholesterol has been described for a number of solid tumours (Alo et al., 1996; Rashid et al., 1997; Pizer et al., 1998) and FAS has been discussed as a metabolic oncogene in prostate cancer (Baron et al., 2004) . Cholesterol is a component of membrane lipid rafts that are involved in signalling processes (Simons and Toomre, 2000) and aberrant regulation of cholesterol synthesis may contribute to cell survival in tumour cells (Freeman and Solomon, 2004) . The use of drugs that inhibit cholesterol synthesis for cancer treatment has been discussed (Brower, 2003) .
In this study, we describe activation of SREBPdependent transcription by the Akt kinase, which itself is frequently activated in human tumours either by overexpression, as a result of oncogenic activation of the Ras pathway, or through inactivation of the PTEN tumour suppressor gene.
Results

PKB/c-Akt induced changes in gene expression
In order to identify changes in gene expression that are the result of activation of Akt, we have used an inducible version of the kinase in which a constitutively active form of Akt (myrAkt) is fused to the hormone binding domain of the oestrogen receptor (myrAkt-ER) (Kohn et al., 1998) . Human retinoic pigment epithelial (RPE) cells expressing myrAkt-ER were treated with 4-hydroxytamoxifen (4-OHT), resulting in activation of the fusion protein detected by phosphorylation on Ser473 as well as phosphorylation of the Akt substrates GSK3a/b (Figure 1a) . Akt has been shown to protect epithelial cells from detachment induced apoptosis, and attachment of cells to components of the extracellular matrix induces endogenous Akt activation (Khwaja et al., 1997) . Figure 1a shows activation of myrAkt-ER in adherent and suspension cells resulting in phosphorylation of Akt substrates under both conditions. Activation of myrAkt-ER also leads to protection from detachment-induced apoptosis in these cells (Figure 1b) .
We analysed changes in gene expression in response to activation of the myrAkt-ER fusion protein in RPE cells by performing comparative hybridization of RNA prepared from 4-OHT-treated cells and ethanol-treated controls to cDNA microarrays. Since detachment from matrix leads to repression of the activity of endogenous Akt protein (data not shown), we activated myrAkt-ER in these cells under adherent and suspension conditions. To eliminate 4-OHT-induced effects, the same experiment was performed with parental cells (data not shown). Among the 10 000 cDNA clones represented on the array, we found 160 that showed reproducible regulation in response to 4-OHT treatment in myrAkt-ER, but not in parental cells in either adherent or suspension cells in four replicate experiments. In all, 145 of these could be mapped to genes or EST sequences, and intensity ratios for these clones are shown in Table 1 . Functional classification of genes found to be up-or downregulated in response to Akt activation revealed that a large number of upregulated genes (24 cDNA clones) code for enzymes that are involved in sterol or fatty acid biosynthesis (Figure 2a ). Expression profiles of these 24 clones (mapping to 15 distinct genes) are represented in the panel in Figure 2b . A number of these genes (marked by asterisks) have been previously reported to be regulated by the SREBP family of transcription factors (Horton et al., 2003) . Although many probes are also regulated by Akt activation in adherent cells, the magnitude of modulation is more pronounced in suspension cells, indicating that repression of endogenous Akt activity by loss of matrix attachment results in the inhibition of expression of those genes.
Akt induces expression of genes involved in sterol and fatty acid biosynthesis
We first investigated whether the observed changes in gene expression in response to Akt activation can be reproduced by an independent method. Figure 3a shows the results of a Northern blot analysis for FAS, malic enzyme, ATP-citrate pro-S-lyase and lysosomal acid lipase, all of which show similar changes in mRNA abundance as measured in the microarray experiment. In addition, a probe detecting both transcripts of the SREBP-1 gene shows an increase in mRNA after Akt activation in adherent and suspension cells (Figure 3a) . Semiquantitative PCR using isoform-specific primers shows an increase in SREBP-1a and SREBP-1c transcripts after Akt activation in adherent and suspension cells, while transcripts for SREBP-2 are only marginally modulated (Figure 3b , upper panel). In addition, Akt activation induced accumulation of transcripts of the FAS, HMG-CoA-reductase and HMG-CoA-synthase (SYN) genes (Figure 3b , lower panel).
In a parallel experiment, whole-cell lysates were analysed for SCAP and FAS as well as for full-length SREBP-1 and SREBP-2 protein (Figure 3c ). It should be noted that the antibody against SREBP-1 detects both isoforms . While FAS, SREBP-1a, SREBP-1c and SREBP-2 protein levels are increased in response to 24 or 48 h of Akt activation in adherent and suspension cells, SCAP expression remains unchanged.
The FAS gene has been shown to be regulated by SREBP transcription factors through SRE sequences in its promoter. A sterol-responsive element at position À54 to À71 consisting of two direct repeat SREs and one E-Box in the rat FAS promoter has been identified to mediate SREBP-induced transcription in cultured (Magana and Osborne, 1996) . In addition, a single SRE located at position À150 to À141 is thought to be involved in nutritional regulation of FAS expression in vivo . The HMG-CoA-synthase promoter is also regulated by SREBPs through an SRE sequence (Swinnen et al., 2000) .
We have transfected a luciferase construct containing a 150 bp fragment of the rat FAS promoter (FAS (À150/ À43)), comprising both SREBP-regulated elements, into U2OS myrAkt-ER cells and measured relative luciferase activity after treatment with 100 nM 4-OHT for 24 h. Figure 3d (left panel) shows that ectopic activation of Akt results in the induction of transcription of the FAS reporter construct. Activation of Akt also induced HMG-CoA-SYN promoter activity (Figure 3d , right panel), although to a lesser extent, but activation was abolished when the SRE was mutated.
Activation of endogenous Akt by EGF or insulin induces accumulation of SREBP-1 protein and transcription from the FAS promoter
We next asked whether endogenous Akt is able to activate SREBP and FAS expression. Figure 4a shows a time course of serine 473 phosphorylation of Akt in RPE cells after treatment with EGF (left panel) or insulin (right panel). Serine 473 is phosphorylated after translocation of Akt to the plasma membrane and is tightly associated with activation of the kinase domain. While activation of Akt in response to EGF is only transient, insulin leads to strong activation that can still be detected 8 h after the treatment. Both EGF and insulin lead to the accumulation of SREBP-1 protein, while SREBP-2 expression is only marginally changed. The induction of SREBP-1 by EGF or insulin can be blocked by treatment with the specific PI3-kinase inhibitor LY294002 (Figure 4b ). This indicates that activation of PI3-kinase downstream of EGF and insulin receptor is required for the induction of SREBP.
Insulin treatment also activates transcription from the FAS promoter (Figure 4c ). This activation is sensitive to treatment with LY294002, again indicating PI3-kinase involvement. In the presence of a specific inhibitor of MAP-kinase, UO126, insulin still induces FAS promoter activity, although to a somewhat lesser extent, indicating that MAP-kinase could contribute to insulin-dependent activation of FAS.
Induction of FAS, HMG-CoA-synthase and HMG-CoA-reductase by Akt requires SREBP-1
We next investigated whether activation of SREBP transcription factors is required for Akt-dependent activation of FAS and SYN expression. First, we made use of dominant-negative forms of the SREBP proteins that were generated by mutation of the DNA-binding domain. Cotransfection of dominant-negative SREBP1a, SREBP-1c or SREBP-2 completely abolished activation of the FAS (Figure 5a , left panel) and HMG-CoAsynthase promoter (Figure 5a, right panel) by Akt. We addressed the same question using specific knockdown of SREBP-1 and SREBP-2 expression by RNA interference (RNAi). Transfection of siRNA oligonucleotides directed against SREBP-1 or SREBP-2 resulted in selective reduction in expression of the respective protein as shown in Figure 5d (second and third panel). Figure 5b shows the effect of ablation of SREBP expression on the activation of FAS (left panel) and HMG-CoA-synthase (right panel) promoters by Akt. Transfection of either SREBP-1 or SREBP-2 siRNA oligonucleotides was sufficient to significantly reduce Akt-induced FAS and HMG-CoA-synthase promoter activation. However, the presence of both siRNA oligonucleotides was required to block completely FAS and SYN promoter activation in response to Akt. In addition, accumulation of FAS, HMG-CoAsynthase and HMG-CoA-reductase mRNAs in response to Akt activation in RPE myrAkt-ER cells was completely abolished after transfection of siRNA We also analysed Akt-dependent induction of FAS protein expression in U2OS myrAkt-ER cells after 48 h of 4-OHT treatment (Figure 5d ). Transfection of unspecific siRNA oligonucleotides did not alter the induction of FAS by Akt (unspecific, lanes 3 and 4). Transfection of siRNA oligonucleotides directed against either SREBP-1 (lanes 5 and 6) or SREBP-2 (lanes 7 and 8) only partially blocked Akt-induced FAS expression. Knockdown of both SREBP-1 and SREBP-2 was required to completely block Akt-induced FAS expression (lanes 9 and 10).
Taken together, these results indicate that SREBP-1, and maybe to a much lesser extent also SREBP-2, are required for the activation of expression of genes involved in sterol and fatty acid biosynthesis by Akt.
Akt-induced nuclear accumulation of mature SREBP-1 is sterol sensitive
In order to investigate the mechanism of activation of SREBP-dependent transcription by Akt, we asked if activation of Akt induced production of mature SREBP-1 and SREBP-2. Activation of myrAkt-ER by 4-OHT treatment led to increased levels of the 65 kDa N-terminal fragment of SREBP-1 in RPE cells grown in adherent or suspension conditions (Figure 6a ). The addition of sterols (cholesterol and 25-hydroxycholesterol) to the growth medium led to a marked reduction in processing of both SREBP-1 and SREBP-2 ( Figure 6b, lanes 2 and 3) . It should be noted that the band-labelled cleaved SREBP-2 represents the C-terminal portion of the protein that remains bound to intracellular membranes. Activation of Akt induced an increase in mature SREBP-1, but did not induce SREBP-2 cleavage (Figure 6b, lane 1) . Activation of Akt was not sufficient to induce accumulation of nuclear SREBP-1 in the presence of sterols. In addition, we transfected reporter constructs containing fragments of the FAS promoter (FAS (À150/À43)) or the HMGCoA-synthase promoter (SYN-WT) into U2OS myrAkt-ER. Akt-dependent activation of these promoter Table 1 and subjected to Northern blot analysis using probes specific for FAS, SREBP-1, malic enzyme, ATP-citrate pro-S-lyase, lysosomal acid lipase and GAPDH, as indicated. (b) RNA prepared from cells treated as in (a) was analysed by semiquantitative PCR for expression of SREBP-1a, SREBP1c, SREBP-2, FAS, HMG-CoAreductase (HMG-CoA-Red) and HMG-CoA-SYN. The values represent relative mRNA abundance and are normalized to GAPDH. (c) Whole-cell lysates of adherent and suspension cells treated with 100 nM 4-OHT for 24 or 48 h were analysed for expression of SCAP, FAS, SREBP-1 and SREBP-2, respectively. Activation of myrAkt-ER was detected using a phosphospecific antibody against Ser473. Actin is shown as a loading control. (d) U2OS myrAkt-ER cells were transfected with 0.1 mg of a luciferase reporter construct containing either a 150 bp fragment of the rat FAS promoter (FAS(À150/À43), left panel) or a fragment of the HMG-CoA-SYN promoter (SYN-WT and SYN-mut1, right panel). At 24 h post-transfection, the medium was replaced with medium containing 0.5% FCS and cells were treated with 100 nM 4-OHT ( þ ) or solvent control (À) for 24 h. The data represent mean7s.d. of two independent experiments and relative luciferase activity was normalized to the activity of a cotransfected lacZ expression plasmid Induction of SREBP by Akt T Porstmann et al fragments was completely blocked in the presence of sterols (Figure 6c ). This indicates that activation of SREBP-dependent transcription of both promoters by Akt is sterol sensitive.
It has been shown that insulin activates processing of SREBP-1c through the downregulation of INSIG-2a in the liver (Yabe et al., 2003) . We analysed expression of INSIG-1 and INSIG-2 after Akt activation in RPE cells by semiquantitative PCR (Figure 6d ). INSIG-2a and INSIG-2b differ in their tissue distribution with INSIG2a being specifically expressed in the liver. Primers used to detect INSIG-2 were derived from sequences common to INSIG-2a and -2b. However, since INSIG-2a expression is restricted to the liver, it is likely that the data in Figure 6d (right panel) represent INSIG-2b expression.
We did not observe significant changes in INSIG expression that could be responsible for the induction of SREBP processing in response to Akt activation. In addition, Akt-dependent induction of FAS and HMGCoA-SYN expression was dependent on de novo protein synthesis as it is completely blocked by cycloheximide treatment (Figure 6e ). Taken together, these results make it unlikely that Akt targets the sterol sensitive SREBP processing machinery directly.
Akt induces accumulation of metabolites that are used for the synthesis of biological membranes
Having shown that Akt induces expression of enzymes involved in cholesterol and fatty acid biosynthesis, we investigated whether this would result in an accumulation of products of these pathways. We used NMR spectroscopy to measure relative changes in the concentrations of intracellular lipids in response to Akt activation. Figure 7 shows the level of various lipid metabolites in extracts from RPE myrAkt-ER cells after 48 h of Akt activation compared to the solvent-treated controls. Significant increases in saturated fatty acids (FA: 13975%, P ¼ 0.0001), unsaturated fatty acids (UFA: 145711%; P ¼ 0.002), phosphatidylethanolamine (PE: 13576%, P ¼ 0.001), phosphatidylcholine (PC: 13774%, P ¼ 0.0007) and phosphatidylglycerol (PG: 13078%; P ¼ 0.008) levels were found in response to Akt activation in these cells. FA and UFAs are required for the synthesis of phosphoglycerides (like PG, PE and PC) and sphingomyelin, which, together with cholesterol, form the building blocks for biological membranes. These findings indicate that activation of SREBP-dependent transcription by Akt may be involved in supplying substrates for the synthesis of membrane components during mitogenesis.
Discussion
The Akt kinase has been described as a crucial component of signal transduction pathways that regulate cell growth, proliferation and survival in response to growth factors. It is activated in cells that have lost the tumour suppressor PTEN and is required for the oncogenic action of mutated Ras proteins. Akt is also a major mediator of the metabolic functions of insulin in the liver, muscle and adipose tissue and involved in reducing the levels of circulating glucose in the blood stream.
In this study, we describe changes to the transcriptional profile induced by Akt activation in a human epithelial cell line (RPE). Out of 10 000 cDNA clones present on the DNA microarray used here, we identified 146 clones that showed reproducible up-or downregulation in response to Akt activation in either (a) RPE cells were treated with 10 ng/ml EGF or 10 mg/ml insulin for 2, 4 and 8 h. Total cell lysates were prepared and analysed for phosphorylation of Akt using a phosphospecific antibody. (b) RPE cells were treated with 20 mM LY294002 or solvent for 30 min and subsequently induced with 10 ng/ml EGF or 10 mg/ml insulin for 4 h. Whole-cell lysates were analysed for expression of SREBP-1 and SREBP-2. Phosphorylation of Akt was detected using a phosphospecific antibody. (c) U2OS cells transfected with 0.1 mg FAS reporter construct (FAS(À150/À43)) were placed in medium containing 0.5% FCS and induced with 10 mg/ml insulin for 24 h in the presence or absence of 20 mM LY294002 or 30 mM UO126, respectively. The data represent mean7s.d. of two independent experiments and relative luciferase activity was normalized to the activity of a cotransfected lacZ expression plasmid Induction of SREBP by Akt T Porstmann et al adherent cells or cells cultured in suspension. As previous results in other epithelial cell lines suggested (Khwaja et al., 1997) , Akt activation induces protection from detachment-induced apoptosis (anoikis) in RPE cells. However, we did not observe obvious changes in gene expression that could contribute to the survival function of Akt. Although we cannot rule out that genes involved in Akt-dependent survival are not represented on the microarray used here, this result indicates that protection from anoikis in RPE cells is more likely to involve direct phosphorylation of apoptotic modulators like Bad (Datta et al., 1997; del Peso et al., 1997) . This is also supported by our observation that protection from anoikis cannot be blocked by inhibition of translation in RPE cells (A Schulze, D Hancock and J Downward, unpublished data). Other studies have identified Akt-regulated genes using gene expression profiling either by treating prostate cancer cells with PI3-kinase inhibitors (Tiwari et al., 2003) or by cardiac-specific expression of membrane-targeted Akt in transgenic mice (Cook et al., 2002) . Another study compared polysomeenriched RNA from cells expressing activated Akt to identify Akt-induced changes in translation (Gera et al., 2004) . While it is difficult to compare microarray data from different cell lines, species and across experimental platforms, we did observe a moderate induction of IGFBP5 (Table 1) in response to Akt activation in keeping with the results obtained by Cook et al. (2002) . In contrast, our data indicate induction of VEGF in response to Akt activation, while expression of activated Akt in the heart resulted in the downregulation of VEGF (Cook et al., 2002) . These inconsistencies are most likely due to differences in the experimental system, that is, short-term activation versus long-term adaptation.
In contrast to previous studies, we observed that a large proportion of genes upregulated by Akt activation code for enzymes that are involved in lipid metabolism. Among them are three enzymes that catalyse the Figure 6 Akt induced accumulation of mature SREBP-1 protein and activation of the FAS promoter is sensitive to sterol. (a) RPE myrAkt-ER cells were plated on normal (A) or poly-HEMA-coated dishes (S) in medium containing 1% FCS and treated with 100 nM 4-OHT ( þ ) or solvent (À) for 48 h. Nuclear lysates were analysed for the presence of the 65 kDa mature form of SREBP-1. (b) RPE myrAkt-ER cells were cultured in medium containing 1% LPDS and treated with 100 nM 4-OHT ( þ ) or solvent (À) for 24 h either in the presence or absence of a mixture of 10 mg/ml cholesterol and 1 mg/ml 25-hydroxycholesterol (sterols). Whole-cell lysates were analysed for the presence of cleaved SREBP-2. Note that cleaved SREBP-2 represents the C-terminal part of the protein that remains associated to intracellular membranes. Activation of myrAkt-ER was analysed using a phosphospecific antibody. Actin is shown as a loading control. Nuclear extracts were prepared and analysed for the presence of mature SREBP-1. The transcription factor DP-1, a nuclear protein, is shown as a loading control. Since it has been shown that the vast majority of these genes is regulated by the SREBP family of transcription factors, we investigated whether Akt can activate SREBP-dependent transcription. Activation of Akt was sufficient to induce transcription from the FAS and HMG-CoA-synthase promoter only in the presence of an intact SRE. Activation of SREBP-1 expression in response to growth factor treatment (EGF or insulin) and induction of transcription from the FAS promoter were sensitive to inhibition of PI3-kinase. This is in keeping with a role for the PI3-kinase/Akt pathway in mediating insulininduced activation of SREBP-1 in the liver and primary hepatocytes (Fleischmann and Iynedjian, 2000; Sul et al., 2000) . Although the ERK/MAP-kinase pathway has been implicated in regulating the transcriptional activity of SREBPs Roth et al., 2000) , the MEK inhibitor UO126 had only a minor effect on FAS promoter activity in the cells used here.
Our data strongly suggest that activation of transcription of genes involved in lipogenesis by Akt is likely to be mediated by SREBPs. We used dominant-negative forms of all three SREBP isoforms (1a, 1c and 2) in which a highly conserved tyrosine residue in the DNA-binding domain was exchanged for alanine. This mutation has been shown previously to abolish DNA binding of SREBP proteins while still allowing dimerization resulting in dominant-negative function (Kim et al., 1995) . Our results indicate that expression of dominant-negative SREBP-1a, SREBP-1c or SREBP-2 is sufficient to repress Akt-dependent activation of the FAS promoter. We also used specific gene silencing by siRNA to downregulate selectively SREBP-1 or SREBP-2 expression. Analysis of activity of the FAS and HMG-CoA-synthase promoters, as well as expression of FAS, HMG-CoA-synthase and HMG-CoAreductase, showed that ablation of SREBP-1 almost completely blocked Akt-dependent regulation of these genes. In contrast, Akt-dependent regulation could still be observed, albeit to a lesser extent, after ablation of SREBP-2 expression. The discrepancy between the results obtained with RNAi and dominant-negative mutants is most likely due to formation of heterodimers between dominant-negative proteins and endogenous SREBP (Datta and Osborne, 2005) .
SREBPs are activated by proteolytic cleavage in response to low intracellular sterol concentrations and the transcriptionally active N-terminal cleavage product translocates to the nucleus. In the presence of sterols, INSIG-1 and INSIG-2 bind to SCAP and inhibit translocation of SREBPs to the Golgi apparatus where cleavage occurs. We observed an increase in the mature 65 kDa form of SREBP-1 upon Akt activation in cells grown under adherent and suspension conditions. Aktinduced processing of SREBP-1 was still sensitive to inhibition by sterols, indicating that Akt does not target the sterol-sensing SREBP processing machinery. Sterols also completely blocked activation of transcription from the SRE containing FAS and HMG-CoA-synthese promoter reporter constructs. In addition, we did not observe any increase in SREBP-2 cleavage in response to Akt activation. It should be noted that the antibody used here does detect the C-terminal cleavage product that most likely remains associated with the endoplasmatic reticulum. So far, we have been unable to detect nuclear SREBP-2 due to the lack of a suitable antibody. However, since ablation of SREBP-2 expression by RNAi was less efficient in blocking Akt-dependent activation of SREBP target genes, it seems likely that Akt activates only SREBP-1.
It has been reported that insulin induces processing of SREBP-1c in the liver by down-regulating expression of INSIG-2a (Yabe et al., 2003) . INSIG-2a is a liverspecific transcript that only differs in its noncoding sequence from INSIG-2b (Yabe et al., 2003) . We did not observe any significant changes in the expression of INSIG-1 and INSIG-2 in response to Akt activation in RPE cells, indicating that regulation of INSIG-2a by insulin is through pathways not involving Akt or may be restricted to hepatocytes.
It has been shown recently that insulin can induce rapid processing of SREBP-1c in hepatocytes via an as yet unknown mechanism that does not involve modulation of INSIG expression (Hegarty et al., 2005) . However, in our experimental system activation of Akt did not induce processing of exogenously expressed HAtagged SREBP-1 (data not shown). It also seems unlikely that Akt activates transcription of SREBPregulated genes through direct modification of SREBP or a protein involved in SREBP processing. We were unable to identify high stringency Akt phosphorylation sites in SREBP proteins, SCAP, INSIG or site 1 and site 2 proteases. We were also unable to detect any Induction of SREBP by Akt T Porstmann et al modification of endogenous SREBP-1 protein in response to Akt activation in RPE cells using 2D electrophoresis (data not shown).
It has been reported that SREBP-1c can be phosphorylated by GSK3, resulting in the inhibition of its transcriptional activity and inhibition of GSK3 by chemical inhibitors activates transcription from the FAS promoter in HEK293 and Rat1-IR cells (Kim et al., 2004) . Although we could observe a moderate increase in FAS mRNA in response to treatment with the GSK3 inhibitor SB-216763 (Supplementary Figure  1) , we did not observe a consistent effect on expression of other SREBP-regulated genes (HMG-CoA-synthase, SREBP-1a and SREBP-1c, respectively). We also observed no effect of inhibition of the mammalian target of rapamycin on Akt-induced FAS expression (Supplementary Figure 2) .
Our results suggest that activation of SREBPdependent gene expression by Akt involves an indirect mechanism that requires de novo protein synthesis. Induction of FAS, HMG-CoA-synthase and HMGCoA-reductase, and also SREBP-1a and SREBP-1c by Akt was blocked in the presence of cycloheximide (Figure 6e and data not shown). Thus, it is possible that Akt induces an intermediate transcription factor which then regulates SREBP-dependent gene expression. We found a number of transcriptional regulators among the genes modulated in response to Akt activation in RPE cells (see Table 1 ). Among these results, downregulation of CREBL1/ATF-6b seems particularly interesting since ATF-6 has been shown to inhibit SREBP-dependent transcription in response to glucose deprivation (Zeng et al., 2004) . We are currently investigating whether downregulation of ATF6b could be involved in Aktdependent regulation of SREBPs.
Since the promoter sequences of all SREBP genes contain SRE elements (Amemiya-Kudo et al., 2000 and our own unpublished observations), it is possible that induction of SREBP gene transcription is the result of a positive feedback loop. It has been reported that the rat SREBP-1c promoter is induced by insulin in hepatocytes through a 149 bp fragment containing NF-Y, LXREs, SRE and SP1 sites and mutation of the SRE completely abolishes the response of the SREBP-1c promoter to insulin (Deng et al., 2002) . However, mutation of the binding sites for LXR, NF-Y and SP1 also significantly reduce the insulin response (Cagen et al., 2005) . It has been shown recently that the promoter of the SREBP-1a gene also contains several SP1 sites (Zhang et al., 2005) and that SP1 may be involved in the induction of VEGF expression by Akt (Pore et al., 2004) . It is therefore possible that Akt modulates expression and/or activity of SP1 or another transcription factor that cooperates with SREBPs.
The most important question arising from the results of this study concerns the effect of SREBP activation by Akt on cell phenotype. The data shown in Figure 7 indicate that activation of Akt leads to the induction of FA and UFA, PC, PG and PE, all involved in the biosynthesis of biological membranes. The PI3-kinase/ Akt pathway has been implicated in cell growth in mammalian cells (Kozma and Thomas, 2002) and the regulation of cell and organ size in Drosophila melanogaster (Leevers et al., 1996; Verdu et al., 1999) . In addition, mice with deletion of both Akt isoforms (Akt1 and Akt2) show dwarfism and skeletal muscle atrophy due to a decrease in cell size (Peng et al., 2003) . We have observed that activation of Akt induces increased cell volume in RPE and U2OS cells (B Griffiths and A Schulze, unpublished data). It seems obvious that an increase in cell size cannot be achieved without de novo membrane synthesis. Activation of lipid synthesis via activation of SREBPs could therefore be an important mechanism for the regulation of cell growth by Akt.
Materials and methods
Cell culture and reagents
RPE myrAkt-ER and U2OS myrAkt-ER cells were kindly supplied by Dr S Basu (Cancer Research UK, London). U2OS cells were obtained from ATCC. RPE myrAkt-ER cells were maintained in DMEM/HAMS F12 (1 : 1) medium supplemented with 10% FCS, glutamine and sodium bicarbonate. U2OS and U2OS myrAkt-ER cells were maintained in DMEM medium supplemented with 10% FCS and glutamine. For culture at low sterol concentration, cells were grown in medium supplemented with 1% lipoprotein-deficient serum (LPDS) obtained from Intracel.
The 110 bp FAS promoter construct pGL2-FAS (À150 to À43) was a gift from Dr T Osborne (UC Irvine, Irvine, CA, USA). pCMV7-SREBP-1a, -SREBP-1c and -SREBP-2 were a gift from Dr Shimano (OKINAKA Memorial Institute for Medical Research, Tokyo, Japan). Dominant-negative SREBP proteins, SREBP-1a (Y335A), SREBP-1c (Y321A) and SREBP-2 (Y342A), were generated by site-directed mutagenesis using the QuickChange Kit from Stratagene by replacing the conserved tyrosine residue in the DNA-binding domain (EKRY) with an alanine residue (EKRA). The HMG-CoA-SYN promoter constructs pGL3-SYNwt-luc, pGL3-SYNmutSRE1 and pGL3-SYNmutSRE2 were a gift from Dr J Swinnen (Catholic University of Leuven, Leuven, Belgium). Monoclonal anti-SREBP-1 (2A4) and -2 (1C6) were from BD Biosciences. Anti-FAS antibody, anti-phosphoGSK3a/b and anti-phospho-Akt antibody were from Cell Signalling. Anti-actin antibody, anti-SCAP and anti-ERa antibody were obtained from Santa Cruz Biotechnology. LY294002 and UO126 were purchased from New England Biolabs.
RNA preparation and array hybridization
Total RNA was prepared using Trizol Reagent (GibcoBRL) following the manufacturer's protocol. Total RNA from control and experimental sample was labelled by oligo-dT 17 -primed first-strand cDNA synthesis in the presence of Cy3-dUTP or Cy5-dUTP (Amersham), respectively. Labelled cDNA was purified using AutoSeq G-50 columns and hybridized for 16 h to human cDNA microarrays (Sanger human 10K version 1.2.1, comprising 10 000 probes representing 6000 human genes). All hybridizations were performed in quadruplicates using duplicate RNA samples and performing reversed Cy3/Cy5 labelling. For detailed description of the cDNA clones, preparation of the microarrays and protocols used in sample preparation, array hybridization, washing and handling, see http://www.sanger.ac.uk/Projects/Microarrays/.
Data analysis
Images were quantified using the adaptive circle method of GSI-Lumonics QuantArray software. Intensity values were imported into Silicon Genetics Genespring software and perspot and per-chip normalization was performed using the Lowess method. Intensity ratios were subsequently normalized to a control hybridization, which represented a self-to-self comparison of the control sample.
Genes significantly regulated in response to myrAkt-ER activation were identified by applying a restriction on fold change of 1.7-fold in three out of four replicate experiments. To rule out effects of tamoxifen, RNA from vector-transfected RPE cells treated with 100 nM 4-OHT was compared in a control experiment (data not shown).
Intensity ratios of the selected genes were used to perform a cluster analysis using Pearson's correlation.
Probes were annotated according to the Hver1.2.1mfg30 annotation provided by the Sanger Microarray facility (for more information see http://www.sanger.ac.uk/Projects/ Microarrays/informatics/annotation.shtml).
Northern blotting
Total RNA (10 mg) was separated by denaturing agarose/ formaldehyde gel electrophoresis, blotted onto charged Nylon membranes and immobilized by UV crosslinking. Fragments of the human cDNAs for FAS, SREBP-1, malic enzyme, ATPcitrate-lyase, lysosomal acid lipase and INSIG-1 were isolated from corresponding IMAGE clones and labelled with [a-32 P]dCTP using a random prime labelling kit (Stratagene). Hybridizations were performed using Quickhyb hybridization solution (Stratagene). Signals were detected by autoradiography and/or phosphoimaging. GAPDH was detected using a labelled fragment of the rat GAPDH cDNA.
Quantitative PCR
Total RNA was isolated using the RNeasy kit (Qiagen) and treated with DNase I (Qiagen). Total RNA (2.5 mg) was used for first-strand cDNA synthesis with SuperScript II Reverse Transcriptase and oligo-dT primer (Invitrogen). To detect transcripts of SREBP-1a, SREBP-1c and SREBP-2, reverse transcription was performed using gene-specific primers. Primers were designed using Primer Express (PE Applied Biosystems) and specificity was verified by conventional PCR. Primer sequences are shown as Supplementary Information. Real-time PCR was performed with SYBR s Green PCR Master Mix (Applied Biosystems). PCR was carried out in 96-well plates using the ABI PRISM 7700 Sequence Detection System (Applied Biosystems). All reactions were performed at least in duplicates. The relative amount of all mRNAs was calculated using the comparative CT method after normalization to GAPDH.
Transfection and reporter assays
The FAS promoter constructs and SYN promoter constructs were described before (Bennett et al., 1995; Swinnen et al., 2000) . U2OS or U2OS myrAkt-ER cells were plated in six-well plates in medium containing 10% FCS at a density of 1 Â 10 5 cells. After 24 h, cells were transfected using Effectene Transfection Reagent (Qiagen). At 24 h post-transfection, medium was replaced with medium containing 0.5% FCS and cells were treated with 4-OHT, inhibitors or solvent for 24 h. Cells were harvested 48 h after transfection in reporter lysis buffer (Promega). Lysates were assayed for luciferase activity by using the luciferase reporter assay kit (Promega) and a Berthold Bioluminat LB luminometer. To normalize luciferase activity, expression of a cotransfected lacZ expression plasmid (LacZ) was measured by standard techniques.
Cell lysis and immunoblotting
Cells were treated as described in the figure legends. For detection of processed SREBP protein, cells were treated with 25 mg/ml N-acetyl-leucyl-leucyl-norleucinal (ALLN) for 2 h before lysis.
For total cell lysis, cells were washed twice with ice-cold PBS and dissolved in either Triton lysis buffer (1% Triton X-100, 50 mM Tris (pH 7.5), 300 mM NaCl, 1 mM EGTA and Protease-Inhibitor-Cocktail (Roche)) or Triton/sodium deochycholate lysis buffer (1% Triton X-100, 0.2% sodium deoxycholate, 140 mM NaCl, 10% glycerol, 50 mM Tris (pH 8), Protease-Inhibitor-Cocktail and 25 mM ALLN). Plates were incubated for 20 min on ice, lysates were collected by scraping and cleared by centrifugation at 13 000 r.p.m. for 10 min.
Nuclear lysates were prepared following the protocol described by Wang et al. (1994) . Briefly, cells were collected by centrifugation at 1000 g for 5 min, suspended in three volumes of buffer 1 (10 mM HEPES-KOH, 10 mM KCl, 1.5 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM EGTA, 25 mg/ml ALLN, þ Protease-Inhibitor-Cocktail) and incubated for 10 min on ice. Plasma membranes were disrupted by passing the cells 15 times through a 23-G needle and nuclei were collected by centrifugation at 1000 g for 5 min. Nuclei were lysed in 1.5 times pellet volume of buffer 2 (10 mM HEPES-KOH, 0.42 M NaCl, 1.5 mM MgCl 2 , 0.5 mM EDTA, 0.5 mM EGTA, 2.5% glycerol, Protease-Inhibitor-Cocktail), incubated on a rotator for 30 min at 41C and cleared by centrifugation at 13 000 r.p.m. for 15 min.
Equal amounts of protein were separated on SDS-polyacrylamide gels and blotted onto PVDF membrane (Immobilon). Membranes were blocked, incubated with antibody solutions and signals were detected by incubation with HRPconjugated secondary antibodies followed by chemiluminescent detection using ECL-reagent. Membranes were exposed to Hyperfilm-ECL (Amersham).
siRNA transfection U2OS myrAkt-ER cells were seeded into 24-well plate in medium contaning 10% FCS. After 24 h, 0.8 mg of siRNA oligonucleotides specific for SREBP-1 or SREBP-2 or an unspecific control oligonucleotide were transfected using TransMessenger Transfection reagent kit (Qiagen) in serumfree medium. The following sequences were used: SREBP-1 -sense, 5 0 -GGAAGAGUCAGUGCCACUGtt-3 0 , antisense, 5 0 -CAGUGGCACUGACUCUUCCtt-3 0 ; and SREBP-2 -sense, 5 0 -GGUCACAUUACCUUCCUUCtt-3 0 , antisense, 5 0 -GAA GGAAGGUAAUGUGACCtg-3 0 . For analysis of protein expression, medium was replaced with medium containing 0.5% FCS 3 h post-transfection, cells were treated with 4-OHT or solvent for 48 h and whole-cell lysates were prepared. For analysis of FAS promoter activity, siRNA-transfected cells were subsequently transfected with pGL2-FAS. At 24 h post-transfection, medium was replaced with medium containing 0.5% FCS and cells were treated with 4-OHT or solvent for 24 h. Cells were lysed and FAS promoter activity was analysed as described above.
Lipid measurement
RPE cells were plated in medium containing 1% LPDS and treated with 100 nM 4-OHT for 48 h. Equal numbers of cells were used to extract cellular lipids using a dual-phase extraction method. Cells were washed twice with ice-cold PBS, dissolved in methanol, scraped off and transferred into centrifuge tubes. An equal volume of ice-cold chloroform was added and tubes were mixed for 30 s. The same volume of ice-cold deionized water was added and tubes were mixed for 30 s. Phase separation was achieved by centrifugation at 10 000 r.p.m. for 20 min at 41C. The chloroform phase, containing cellular lipids, was transferred into a glass tube and air-dried. Lipid extracts were reconstituted in 600 ml deuterated chloroform (which was used as an internal standard for spectral normalization) and freshly prepared 0.008% (v/v) tetramethylsilane was used as a chemical shift reference (0 ppm). Proton NMR spectra of the lipid extracts were acquired using a Bruker 600-MHz (Bruker Avance; Bruker GmbH, Germany) NMR system. Spectra were obtained using a 301 pulse, spectral width of 9 KHz, repetition time of 6 s and 32k data points. Peaks were assigned according to Sze and Jardetzky (1990) . The relative lipid levels were then standardized to the number of cells.
